WORLDCOIN-FOUNDATION
15.5.2024 15:03:34 CEST | Business Wire | Press release
The Worldcoin Foundation today announced it launched and is open sourcing a novel secure multi-party computation (SMPC) system. The system, available now in a GitHub repository for any organization to use, aims to set a new standard for data protection, including the protection of biometric data. The Worldcoin Foundation also announced that, after the migration of iris codes to the new SMPC system, the previous uniqueness-checking system, including iris codes, was securely deleted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515285506/en/
Worldcoin Foundation Launches, Open Sources "Perfect Secrecy" SMPC System to Help Organizations Strengthen Biometric Data Security Protections (Graphic: Business Wire)
Biometric authentication use increases as data breach frequency and impact rise
Organizations in the private and public sector increasingly require and use consumers’ biometric data for everyday services and activities, from building access and airport security to logging into healthcare and financial services apps. Underscoring the increase, a Fortune Business Insights report projected the global biometric system market size to reach $76.70 billion USD in 2029, 2.5x its total of $30.77 billion in 2022.
Meanwhile, research from MIT Professor Stuart Madnick indicates a 20% increase in data breaches from 2022 to 2023 while globally the number of victims of such breaches doubled over the same time period.
The convergence of these trends suggests a need to further advance data protection technologies. While Worldcoin is neither an authentication nor an identification use case for biometrics (the Worldcoin Foundation does not know the identity of their users), the Foundation’s new open source SMPC system can serve as a building block to set a new standard in biometric data security.
Worldcoin Foundation’s SMPC system
SMPC has been lauded by privacy and security experts alike. It can be thought of as taking one secret and sharing it in multiple parts across different parties for increased protection. Importantly, none of the individual parts alone say anything about the original secret, thus making it impossible for any individual party to decrypt the secret.
This SMPC approach demonstrates perfect information-theoretic security, meaning it is effective even against quantum-computing. SMPC systems have generally been too resource-intensive to be effectively used for large complex computations. This is why, despite their impressive privacy protective qualities, they have not yet seen extensive use in biometric template protection.
The Worldcoin Foundation, along with contributor-technologists from TACEO and Tools for Humanity, have successfully architected a new implementation of SMPC to address the scale and cost constraints that have previously hindered others. The new SMPC system, which encrypts iris codes into secret shares held by multiple parties, enabled the Worldcoin Foundation to permanently delete iris codes generated through its previous uniqueness-checking system.
“The community supporting Worldcoin will never stop developing, testing and deploying the most advanced technologies focusing on security, privacy and data protection as it works to improve trust online and increase access to the global economy,” said Jannick Preiwisch, Data Protection Officer of the Worldcoin Foundation. “Implementation of the new SMPC system enabled the Worldcoin Foundation to delete old iris codes by permanently encrypting them to SMPC shares that by themselves cannot be related to an identified person. The development of this new system demonstrates an unparalleled commitment to further compliance with the EU General Data Protection Regulation and other data protection regimes across the world. It also complements advancements aimed at providing consumers increased choice and control over their data including personal custody and the ability to unverify their World IDs.”
About the Worldcoin Foundation
The Worldcoin Foundation, a steward of the Worldcoin protocol, aims to realize more inclusive, fair and just institutions of governance and of the global digital economy.
About the Worldcoin Protocol
The Worldcoin protocol is intended to be the world’s largest, most inclusive identity and financial public utility and to be accessible by everyone. Worldcoin was originally conceived by Sam Altman, Alex Blania and Max Novendstern. The Worldcoin protocol is designed to empower individuals and organizations around the world with the tools they need to participate in the digital economy and advance humanity's progress. Find out more about Worldcoin at www.worldcoin.org, on Twitter/X, Discord, YouTube and Telegram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515285506/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom